Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion - Takeaways - MDSpire

Correction: Case Report on Complete Response and Extended Survival with Alectinib in a NSCLC Patient Exhibiting a Rare WDR43::ALK Structural Deletion

By
Frontiers Production Office
September 11, 2026

Frontiers In Oncology

Share

1

The article is a correction to a case report on alectinib's effects in a NSCLC patient with a WDR43::ALK structural deletion.
2

An error in Figure 1 was corrected, where EML4::ALK was incorrectly labeled as ML4::ALK.
3

Figure 3 was mistakenly replaced with a duplicate of Figure 1 and has been corrected.
4

The case report discusses complete response and prolonged survival in the patient treated with alectinib.
5

The original version of the article has been updated to reflect these corrections.